Immatics (IMTX) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on T cell receptor (TCR)-based immunotherapies for solid tumors and high unmet medical needs.

• Develops two therapeutic modalities: autologous TCR-engineered adoptive T cell therapies (ACTengine) and antibody-like TCR Bispecifics (TCER).

• Aims to become a fully integrated global biopharmaceutical company, developing, manufacturing, and commercializing TCR-based immunotherapies.

• Incorporated in the Netherlands, with principal offices in Germany and the U.S.; operates as a foreign private issuer under U.S. securities laws.

Financial performance and metrics

• Financial statements are prepared in euros under IFRS, not U.S. GAAP.

• Recent equity offerings include significant capital raises in 2022, 2023, and 2024, with share issuances to institutional investors and partners.

• PricewaterhouseCoopers GmbH issued an adverse opinion on the effectiveness of internal control over financial reporting for the year ended December 31, 2024.

Use of proceeds and capital allocation

• Net proceeds from offerings will fund continued R&D, manufacturing, production, potential commercialization of product candidates, working capital, and general corporate purposes.

• Pending use, proceeds may be invested in capital preservation instruments, including short- and long-term interest-bearing securities.